DOWNLOAD THIS SLIDE KIT

BROWSE SLIDES

Design

Stopping rule : HCV RNA detectable with < 2 log 10 IU/ml reduction at W4

Objective

• SVR₁₂ (HCV RNA < 12 IU /ml) , with 95% CI, by intention-to-treat analysis

Baseline characteristics and outcome

* Patient with failure : non adherent, withdrew from study

Adverse events, N

Summary

• Patients with chronic HCV genotype 4 infection were successfully treated with a 12 week course of LDV/SOF
  • SVR₁₂ was 100 % for patients who received all 12 weeks of study drugs, irrespective of previous treatment status and underlying liver fibrosis
  • All patients on therapy had HCV RNA below the lower limit of quantification by W4
• This is the first report of a single-pill, all-oral, interferon-free, ribavirin-free treatment for patients with HCV genotype 4
• Limitations
  • Small sample size
  • No randomisation